Cardiovascular DiseasePhase 3REDEFINE 3NCT05669755
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
A Phase 3 study testing Cagrilintide and Semaglutide in people with Cardiovascular Disease, run by Novo Nordisk A/S at 633 sites in 25 countries.
Trial summary
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Read more about this study
- Who is it for?
- Ages 55 years and older
- Conditions the study is for
- Cardiovascular Disease
- What is being tested?
- Cagrilintide and Semaglutide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 7,101 participants
- Where
- 633 sitesin 25 countries
- Study dates
- 1 Mar 2023to 14 Oct 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female
- Age above or equal to 55 years at the time of signing informed consent
- Body mass index (BMI) greater than or equal to (>=) 25.0 kilograms per meter square (kg/m^2)
- Established CVD as evidenced by at least one of the following:
- Prior myocardial infarction
- Prior stroke (ischemic or haemorrhagic stroke)
Show all 18Show fewer
- Symptomatic peripheral arterial disease (PAD) defined as at least one of the following:
- Intermittent claudication with an ankle-brachial index (ABI) less than (<) 0.85 at rest
- Intermittent claudication with a >= 50% stenosis in a lower extremity peripheral artery documented by X-ray angiography, magnetic resonance (MR) angiography, computed tomography (CT) angiography or Doppler ultrasound
- Prior revascularization procedure of a lower extremity peripheral artery
- Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g., trauma or osteomyelitis)
- For participants with T2D at screening the following inclusion criteria also apply:
- Diagnosed with type 2 diabetes mellitus (T2D) >= 180 days before screening
- HbA1c 6.5%-10% (47-86 millimoles per mole [mmol/mol]) (both inclusive), as measured by central laboratory at screening
- Treatment with either:
- Lifestyle intervention alone
- 1-3 marketed oral antidiabetic drugs (OADs) (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose co-transporter 2 inhibitor (SGLT2i), dipeptidyl peptidase 4 (DPP4)-inhibitors, thiazolidinediones, or sulphonylureas (SU) as a single agent or in combination) according to local label
- Basal insulin alone or in combination with up to two marketed OADs, all according to local label
Who cannot join
- Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 60 days before screening
- Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
- Heart failure classified as being in New York Heart Association (NYHA) Class IV at screening
- Treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist (RA) or a medication with GLP-1 activity within 90 days before screening
- End stage renal disease defined as estimated glomerular filtration rate (eGFR) < 15 millileters per minutes per 1.73^2 (mL/min/1.73 m^2), as measured by the central laboratory at screening
- Chronic or intermittent haemodialysis or peritoneal dialysis
Trial locations and contacts
633 sites in 25 countries.
633 sites in 25 countries
United States119 sites
Albany Medical College
Albany, New York, 12203
Renal Medicine Associates
Albuquerque, New Mexico, 87109
PharmaTex Research
Amarillo, Texas, 79106
Arlington Family Res. Ctr Inc
Arlington, Texas, 76012-4637
Northwest Heart Clinical Research, LLC
Arlington Heights, Illinois, 60005
Ascension Saint Agnes Heart Ca
Baltimore, Maryland, 21229
Heritage Valley Medical Group
Beaver, Pennsylvania, 15009
National Heart Institute Cal
Beverly Hills, California, 90211
Univ of Alabama Birmingham
Birmingham, Alabama, 32533
Bridgeport Hospital
Bridgeport, Connecticut, 06610
UNC- Chapel Hill
Chapel Hill, North Carolina, 27599
Univ Diab & Endo Consultants
Chattanooga, Tennessee, 37411
StudyMetrix Research LLC
City of Saint Peters, Missouri, 63303
Innovative Research of W FL
Clearwater, Florida, 33756
Cleveland Clinic - Main Campus
Cleveland, Ohio, 44195
South Texas Clinical Research
Corpus Christi, Texas, 78404
West Broadway Clinic
Council Bluffs, Iowa, 51501
Valley Clinical Trials
Covina, California, 91723
Louisiana Heart Center
Covington, Louisiana, 70433
Baylor Scott & White Res Inst
Dallas, Texas, 75226
Velocity Clinical Res-Dallas
Dallas, Texas, 75230
Providence Health Partners Ctr
Dayton, Ohio, 45439
Florida Premier Cardiology
Delray Beach, Florida, 33445
Memorial Hospital at Gulfport
Diamondhead, Mississippi, 39525
Dallas Heart and Vascular
Duncanville, Texas, 75137
Duke University
Durham, North Carolina, 27710
Academy of Diabetes, T&E
El Paso, Texas, 79935
Lillestol Research LLC
Fargo, North Dakota, 58104
Fleming Island Center for Clinical Research
Fleming Island, Florida, 32003
Elite Research Center
Flint, Michigan, 48532
Diabetes and Thyroid Ctr of FW
Fort Worth, Texas, 76132
American Hlth Ntwk of IN LLC
Franklin, Indiana, 46131
Macoupin Research Group
Gillespie, Illinois, 62033
Clinical Invest Special_Gurnee
Gurnee, Illinois, 60031
Louisiana Heart Center
Hammond, Louisiana, 70403
Forefront Med Res Inst PLLC
Harlingen, Texas, 78550
PrimeCare Medical Group
Houston, Texas, 77024
Synergy Groups Medical
Houston, Texas, 77061
Southwest Houston Research Ltd
Houston, Texas, 77099
Rocky Mountain Diab&Osteo Ctr
Idaho Falls, Idaho, 83404-7596
Clinical Research Consultants, LLC
Kansas City, Missouri, 64111
Prem Internal Med Asso Houston
Katy, Texas, 77493
Scripps Wht Diab Inst La Jolla
La Jolla, California, 92037
Radiance Clinical Research
Lampasas, Texas, 76550
First Valley Medical Group
Lancaster, California, 93534
The Research Group of Lexington LLC
Lexington, Kentucky, 40503
Clinical Trials Research_Sacramento
Lincoln, California, 95648
Torrance Clin Res Inst, Inc.
Lomita, California, 90717
DCOL Ctr for Clin Res
Longview, Texas, 75605
Pacific Clinical Studies
Los Alamitos, California, 90720
L-MARC Research Center
Louisville, Kentucky, 40213
Texas Inst, Kdny & Endo Disor
Lufkin, Texas, 75904
Ohio- Advanced Medical Research
Maumee, Ohio, 43537
Texas Institute of Cardiology PA
McKinney, Texas, 75071
Life Spring Research Foundation LLC
Miami, Florida, 33130
Oceane 7 Medical & Research Center, Inc.
Miami, Florida, 33144
Reyes Clinical Research, Inc
Miami, Florida, 33174
San Marcus Res Clin Miami Lakes
Miami Lakes, Florida, 33014
Floridian Clinical Research, LLC
Miami Lakes, Florida, 33016
Monterey Endocrine & Diabetes Institute, Inc
Monterey, California, 93940
Chambliss Clinical Trials LLC
Montgomery, Alabama, 36106
Carteret Medical Group
Morehead City, North Carolina, 28557
Adult Medicine of Lake County, Inc
Mt. Dora, Florida, 32757
Carolina Health Specialists
Myrtle Beach, South Carolina, 29572
Southern New Hampshire Diabetes and Endocrinology
Nashua, New Hampshire, 03063
Eastern Nephrology Associates, PLLC
New Bern, North Carolina, 28562
Tulane University Health Sciences Center
New Orleans, Louisiana, 70112
Suncoast Clinical Research, Inc.
New Port Richey, Florida, 34652
Mid Hudson Med Res-New Windsor
New Windsor, New York, 12553
IMA Clinical Research- NY
New York, New York, 10036
Capital Area Research LLC
Newport, Pennsylvania, 17074
York Clinical Research LLC
Norfolk, Virginia, 23540
Valley Clinical Trials, Inc.
Northridge, California, 91325
VA Neb West Iowa Hlth System
Omaha, Nebraska, 68105
Methodist Physicians Clin
Omaha, Nebraska, 68114
Univ of NE Med Center_Omaha
Omaha, Nebraska, 68198-6828
Midwest Heart & Vasc Spec
Overland Park, Kansas, 66211
Desert Oasis Hlthcr Med Group
Palm Springs, California, 92262
Center for Diab,Obes & Metab
Pembroke Pines, Florida, 33024
Aria Endocrine Metabolic Assoc
Philadelphia, Pennsylvania, 19114
Western University of Health Sciences
Pomona, California, 91766
Hanson Clinical Research Center
Port Charlotte, Florida, 33952
Dominion Medical Associates
Richmond, Virginia, 23219
Endo Res Solutions Inc
Roswell, Georgia, 30076
Texas Diabetes & Endocrinology_Round Rock
Round Rock, Texas, 78681
Northeast Research Institute
Saint Augustine, Florida, 32080
VA Medical Center_Salem
Salem, Virginia, 24153-6404
Clinical Advancement Center
San Antonio, Texas, 78212
San Antonio Prem Int Med
San Antonio, Texas, 78220
Audie L. Murphy VA Hospital
San Antonio, Texas, 78229
Bexar County Hospital District
San Antonio, Texas, 78229
Northeast Clinical Research of San Antonio
San Antonio, Texas, 78233
Linda Vista Health Care Ctr
San Diego, California, 92111
N America Res Inst - San Dimas
San Dimas, California, 91773
Saratoga Clinical Research
Saratoga Springs, New York, 12866
Honor Health
Scottsdale, Arizona, 85258
Endeavor Health
Skokie, Illinois, 60077
Encompass Clinical Research_Spring Valley
Spring Valley, California, 91978
Clinvest Research
Springfield, Missouri, 65807
Amicis Centers of Clinical Research
St Louis, Missouri, 63128
St Louis Heart & Vascular, P.C.
St Louis, Missouri, 63136
Piedmont Healthcare/Research
Statesville, North Carolina, 28625
Simcare Medical Research, LLC
Sugar Land, Texas, 77478
Prime Global Research Inc.
The Bronx, New York, 10456
Lundquist Inst.-Biom Inno-UCLA
Torrance, California, 90502
Arcturus HC PLC Troy Med Res
Troy, Michigan, 48098
Atlanta Heart Specialists, LLC
Tucker, Georgia, 30084
Crossroads Clinical Res- Texas
Victoria, Texas, 77901
Hillcrest Family Health Center
Waco, Texas, 76708
Aspirus Research Institute
Wausau, Wisconsin, 54401
Cardio Partners Clin Res Inst
Wellington, Florida, 33449
Confluence Health Hospital
Wenatchee, Washington, 98801
Valley Diab. & Endo Comp Ctr
Weslaco, Texas, 78596
Iowa Diab & Endo Res Center
West Des Moines, Iowa, 50266
Clinical Trials Of America
West Monroe, Louisiana, 71291
Southgate Medical Group, LLP
West Seneca, New York, 14224
Great Lakes Medical Research
Westfield, New York, 14787
Selma Medical Associates
Winchester, Virginia, 22601-3834
Brookview Hills Research Associates, LLC
Winston-Salem, North Carolina, 27103
India78 sites
CIMS- Care Institute of Medical Sciences
Ahmedabad, Gujarat, 380060
Marengo Asia Health Care Private Limited
Ahmedabad, Gujarat, 380060
Jawahar Lal Nehru Govt. Medical College
Ajmer, Rajasthan, 305001
J N Medical College
Aligarh, Uttar Pradesh, 202002
J N Medical College
Aligarh, 202002
All India Institute of Medical Sciences_Delhi
Ansārinagar, New Delhi, 110029
Ramaiah Memorial Hospital
Bangalore, Karnataka, 560054
Lifecare Hospital and Research Centre
Bangalore, Karnataka, 560092
Narayana Hrudayalya Institute of Cardiac Sciences
Bangalore, Karnataka, 560099
Narayana Hrudayalya Institute of Cardiac Sciences
Bangalore, 560 099
AMRI Hospital
Bhubaneswar, Odisha, 751030
SP Medical College
Bikaner, Rajasthan, 334003
Madras Diabetes Research Foundation
Chennai, Tamil Nadu, 600086
Kamalnayan Bajaj Hospital
Chhatrapati Sambhajinagar, Maharashtra, 431005
Kamalnayan Bajaj Hospital
Chhatrapati Sambhajinagar, Maharashtra, 431010
Kg Hospital and Post Graduate Medical Institute
Coimbatore, Tamil Nadu, 641018
Shri Mahant Indiresh Hospital
Dehradun, Uttarakhand, 248001
Apollo Hospital
Delhi, New Delhi, 110076
Endolife Specialty Hospitals
Guntur, Andhra Pradesh, 522001
Lalitha PVS Institute of Medical Sciences
Guntur, Andhra Pradesh, 522001
Lalitha Super Specialities Hospital
Guntur, Andhra Pradesh, 522001
Himachal Heart Institute
Gutkar, 175021
Excelcare Hospital
Guwahati, Assam, 781033
Ramdev Rao Hospital
Hyderabad, Andhra Pradesh, 500072
Guru Nanak CARE Hospitals
Hyderabad, Telangana, 500020
AIG Hospitals,Hyderabad
Hyderabad, Telangana, 500032
Diabetes Research Center, Hyderabad
Hyderabad, Telangana, 500082
Yashoda Hospital
Hyderabad, Telangana, 500084
Mohak Bariatrics and Robotics
Indore, Madhya Pradesh, 452007
SMS Medical College & Attached Hospitals
Jaipur, Rajasthan, 302004
Diabetes, Thyroid and Endocrine Centre
Jaipur, Rajasthan, 302006
All India Institute of Medical Sciences (AIIMS)
Jodhpur, Rajasthan, 342005
All India Institute of Medical Sciences (AIIMS)
Jodhpur, 342005
Krishna Institute of medical sciences
Karad, Maharashtra, 415539
Krishna Institute of medical sciences
Karad, 415539
All India Institute of Medical Sciences_Khurda
Khurda, Odisha, 751019
Excel Endocrine Centre
Kolhāpur, Maharashtra, 416008
IPGME&R and SSKM Hospital
Kolkata, West Bengal, 700020
Apollo Multispeciality Hospital, Kolkata
Kolkata, West Bengal, 700054
Government Medical College, Kozhikode
Kozhikode, Kerala, 673008
King George's Medical University (KGMU)
Lucknow, Uttar Pradesh, 226003
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Lucknow, Uttar Pradesh, 226014
Sanjay Gandhi Postgraduate Institute of Medical Science
Lucknow, Uttar Pradesh, 226014
Christian Medical College and Hospital
Ludhiana, Punjab, 141008
Omega Hospital (P) Limited
Mangalore, Karnataka, 575002
Fortis Heart Institute and Multispeciality Hospital
Mohali, Punjab, 160062
Sir H. N. Reliance Foundation Hospital and Research Centre
Mumbai, Maharashtra, 400004
Wockhardt Hospital, Mumbai Central
Mumbai, Maharashtra, 400011
Seth GS Medical College & KEM Hospital
Mumbai, Maharashtra, 400012
Mysore Medical College and Research Institute
Mysore, Karnataka, 570001
Hrudaya Cardiac and Vascular Care Centre
Nagpur, Maharashtra, 440019
Sengupta Hospital and Research Institute
Nagpur, Maharashtra, 440033
All India Institute of Medical Sciences (AIIMS), Nagpur
Nagpur, Maharashtra, 441108
Shalini Tai Meghe Hospital and Research Center
Nagpur, Maharashtra, 441110
Diabetes Care N' Research Centre Pvt. Ltd.
Nagpur, 440010
Hrudaya Cardiac and Vascular Care Centre
Nagpur, 440019
Magnum Heart Institute
Nashik, Maharashtra, 422005
Magnum Heart Institute
Nashik, 422005
G B Pant Institute of Postgraduate Medical Education and Research
New Delhi, National Capital Territory of Delhi, 110002
G.B Pant Institute of Post Graduate medical education and research
New Delhi, 110002
BL Kapur Super Specialty Hospital
New Delhi, 110005
Dr. BL Kapur Memorial Hospital
New Delhi, 110005
Sir Ganga Ram Hospital
New Delhi, 110060
Grant Medical Foundation Ruby Hall Clinic
Pune, Maharashtra, 411001
Chellaram Diabetes Institute
Pune, Maharashtra, 411021
B J Medical College & Sassoon Hospital
Pune, 411001
WMF's Villoo Poonawalla Memorial Hospital
Pune, 411028.
SMC Heart Institute and IVF Research Centre
Raipur, Chhattisgarh, 390001
SMC Heart Institute and IVF Research Centre
Raipur, Chhattisgarh, 492007
Unicare heart institute and research centre
Surat, Gujarat, 395001
Nirmal Hospital Pvt. Ltd.
Surat, Gujarat, 395002
Citi neuro centre
Telangana, 500034
Ashirwad Hospital and Research Centre
Thane, Maharashtra, 421004
SSG Hospital, Baroda
Vadodara, Gujarat, 390001
Bankers Heart Institute
Vadodara, Gujarat, 390015
Rhythm Heart Institute
Vadodara, Gujarat, 390022
Christian Medical College Hospital, Vellore
Vellore, Tamil Nadu, 632004
Sunrise Hospital
Vijayawada, Andhra Pradesh, 520002
Poland57 sites
American Heart of Poland S.A.
Bełchatów, Łódź Voivodeship, 97-400
Uniwersytecki Szpital Kliniczny w Bialymstoku K. Kardio
Bialystok, Podlaskie Voivodeship, 15-276
Gabinet Leczenia Otylosci i Chorob Dietozaleznych
Bialystok, Podlaskie Voivodeship, 15-281
Kresmed Sp. z o. o.
Bialystok, Podlaskie Voivodeship, 15-481
Osteo-Medic s.c. A. Racewicz, J. Supronik
Bialystok, 15-351
Renew Clinic Sp. z o.o.
Bialystok, 15-797
American Heart of Poland S.A.
Bielsko-Biala, 43-316
Centrum Medyczne Kermed Renata Bijata-Bronisz I Ewa Kowalinska Sp. j.
Bydgoszcz, 85-231
Gierach-Med
Bygdoszcz, Kuyavian-Pomeranian Voivodeship, 85-796
Pratia S.A.
Chojnice, 89-600
M2M Med. Badania Sp. z o.o.
Chorzów, Silesian Voivodeship, 41-500
Malopolskie Centrum Sercowo-Naczyniowe
Chrzanów, Lesser Poland Voivodeship, 32-500
NSZOZ Unica CR
Dąbrówka, Greater Poland Voivodeship, 62-069
NSZOZ Unica CR
Dąbrówka, 62-069
Centrum Kliniczno-Badawcze J. Brzezicki, B. Górnikiewicz-Brzezicka Lekarze Spółka Partnerska
Elblag, 82-300
UCK Klinika Nadcisnienia Tetniczego i Diabetologii
Gdansk, 80-214
Centrum Medyczne Pratia Gdynia
Gdynia, Pomeranian Voivodeship, 81-338
Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski
Gorzów Wielkopolski, Lubusz Voivodeship, 66-400
Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski
Gorzów Wielkopolski, 66-400
Kardio Klinika Brynow
Katowice, Silesian Voivodeship, 40-555
Pro Familia Altera Sp. z o.o.
Katowice, Silesian Voivodeship, 40-648
Care Clinic Sp. z o. o.
Katowice, 40-568
Uniwersyteckie Centrum Kliniczne SUM w Katowicach
Katowice, 40-752
Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
Krakow, Lesser Poland Voivodeship, 31-261
Grazyna Pulka Specjalistyczny Osrodek "All-Med"
Krakow, 30-033
Szpitale Powiatowe Sp. z o.o.
Łask, 98-100
Gabinet Lekarski Malgorzata Saryusz-Wolska
Lodz, 90-132
Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi
Lodz, 92-213
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi
Lodz, 92-213
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika
Lodz, Łódź Voivodeship, 93-513
Velocity Nova Sp. z o.o.
Lublin, Lublin Voivodeship, 20-362
Zanamed Medical Clinic Sp. z o.o.
Lublin, 20-601
Provita Centrum Medyczne Sp. z o.o.
Piotrkow Trybunalski, 97-300
ETG Poniatowa
Poniatowa, Lublin Voivodeship, 24-320
Centrum Zdrowia Metabolicznego Paweł Bogdański
Poznan, Wielkopolskie Voivodeship, 60-589
Centrum Zdrowia Metabolicznego
Poznan, Wielkopolskie Voivodeship, 60-589
Maciej Wiza Gaja Poradnie Lekarskie
Poznan, 61-251
Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
Ruda Śląska, Gornoslaskie, 41-709
Velocity Nova Sp. z o.o.
Staszów, Świętokrzyskie Voivodeship, 28-200
Polsko - Amerykanskie Kliniki Serca X Oddzial Kardiologii Inwazyjnej, Elektrofizjologii i Elektrostymulacji w Tychach
Tychy, 43-100
Provita Poliklinika Sp. z o.o
Warsaw, Masovian Province, 02-647
MEDI CLINICAL Badania Kliniczne
Warsaw, Masovian Province, 02-786
Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orlowskiego Centrum Medycznego Ksztalcenia Podyplomowego
Warsaw, Masovian Voivodeship, 00-416
Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orłowskiego Centrum Medycznego Kształcenia Podyplomowego
Warsaw, Masovian Voivodeship, 00-416
ETG Warszawa Sp. z o.o.
Warsaw, Masovian Voivodeship, 02-677
Szpital Czerniakowski Sp. z o.o.
Warsaw, 00-739
Bodyclinic Sp. z o.o. sp.k.
Warsaw, 03-712
NASMED
Warsaw, 03-984
Regionalna Poradnia Diabetologiczna-Zytkiewicz-Jaruga, Stasinska Spolka Partnerska Lekarzy
Wroclaw, Lower Silesian Province, 50-127
4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu
Wroclaw, Lower Silesian Voivodeship, 50-981
4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu
Wroclaw, Lower Silesian Voivodeship, 53-114
Pracownia Badan Klinicznych SALUS
Wroclaw, 53-034
Slaskie Centrum Chorob Serca W Zabrzu
Zabrze, Silesian Voivodeship, 41-800
Wojewodzka Poradnia dla Chorych na Cukrzyce w Zabrzu
Zabrze, Silesian Voivodeship, 41-800
Wojewodzka Poradnia dla Chorych na Cukrzyce w Zabrzu
Zabrze, 41-800
Velocity Nova Sp. z o.o. Velocity Zamosc
Zamość, 22-400
Prywatna Praktyka Lekarska Anna Chudoba
Żyrardów, Masovian Voivodeship, 96-300
Bulgaria41 sites
SRH - Zdrave EAD
Bankya, 1320
DCC - Burgas EOOD
Burgas, 8000
IPSOMC - Dr. Georgi Marinov
Burgas, 8000
MC Diamedical - 2013 OOD, Dimitrovgrad
Dimitrovgrad, 6400
Medical centre Asclepius OOD
Dupnitsa, Kyustendil, 2600
AIPSMC - DiMed EOOD
Haskovo, 6300
Medical centre Zdrave 1 OOD
Kozloduy, 3320
MHAT - Uni Hospital OOD
Panagyurishte, 4500
"MHAT - Pazardzhik"
Pazardzhik, 4401
MHAT - Pazardzhik AD
Pazardzhik, 4401
Medical center Medconsult Pleven OOD
Pleven, 5800
OCSOMCE - Dr. Albena Dinkova EOOD
Pleven, 5800
DCC Pulmed EOOD
Plovdiv, 4000
MHAT Med Line Clinic
Plovdiv, 4000
UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic
Plovdiv, 4001
UMHAT - Plovdiv AD
Plovdiv, 4002
UMHAT Pulmed OOD - Plovdiv, Department of Endocrinology
Plovdiv, 4002
MHAT Sveta Karidad EAD
Plovdiv, 4004
UMHAT Medica - Ruse OOD
Rousse, 7013
AIPSOMCIDEMD - Dr. Lilyana Bodurova-Troharova EOOD
Samokov, 2000
MHAT Dr. Ivan Seliminski - Sliven AD
Sliven, 8800
Nader Yabrudi - ASMPVBE Individual practice
Smolyan, 4700
MHAT Knyaginya Klementina - Sofia EAD
Sofia, 1233
MHAT Sveta Sofia EOOD
Sofia, 1404
Acibadem City Clinic UMHAT Tokuda EAD, Endocrinology
Sofia, 1407
UMHAT Aleksandrovska EAD, Clinic of Endocrinology and Metabolic Diseases
Sofia, 1431
UMHAT Sveti Ivan Rilski EAD, Nephrology
Sofia, 1431
MC Orthopaedic Center Kinov EOOD
Sofia, 1527
Medical Institute of Ministry of interior
Sofia, 1606
MC Diamedical - 2013 OOD, Sofia
Sofia, 1618
Medical centre Vitclinic EOOD
Sofia, 1680
MBAL Trakia EOOD
Stara Zagora, 6000
Medical center Zara-Med EOOD
Stara Zagora, 6000
Prevencia - 2000 - MCOC OOD
Stara Zagora, 6000
Medical Center Nov Rehabilitatsionen center EOOD
Stara Zagora, 6001
UMHAT Prof. Dr. Stoyan Kirkovich AD
Stara Zagora, 6003
UMHAT Sveta Marina EAD, Clinic of Internal Diseases
Varna, 9010
UMHAT Sveta Marina EAD
Varna, 9010
DCC 1 Velingrad EOOD
Velingrad, 4600
Medical centre Runkovi OOD
Yambol, 8600
MHAT Sveti Panteleimon - Yambol AD
Yambol, 8600
Turkey (Türkiye)36 sites
T.C. Saglık Bakanlıgı Adana Sehir Egitim ve Arastirma Hastan
Adana, 01000
Baskent Universitesi Adana
Adana, 01250
Başkent Üniversitesi Adana Dr. Turgut Noyan Uygulama ve Araştırma Merkezi
Adana, 01250
Afyonkarahisar Health Sciences University
Afyonkarahisar, 03200
Afyonkarahisar Sağlık Bilimleri Üniversitesi Sağlık Uygulama Ve Araştırma Merkezi- Kardiyoloji
Afyonkarahisar, 03200
Baskent University Ankara Hospital
Ankara, Bahcelievler, 06490
Başkent Üniversitesi Ankara Hastanesi-Endokrinoloji
Ankara, Bahcelievler, 06490
Ankara Bilkent Şehir Hastanesi-Dahiliye
Ankara, 06800
Ankara Sehir Hastanesi Dahiliye Klinigi
Ankara, 06800
Bursa Yüksek İhtisas Eğitim ve Araştırma Merkezi-Kardiyoloji
Bursa, Yildirim, 16110
Trakya Üniversitesi Tıp Fakültesi Hastanesi- Kardiyoloji
Edirne, 22030
Eskisehir Osmangazi University Sağlık Uygulama ve Arastirma
Eskişehir, Odunpazari, 26040
Eskişehir Osmangazi Üniversitesi Hastanesi- Kardiyoloji
Eskişehir, Odunpazari, 26040
Eskişehir Şehir Hastanesi- Kardiyoloji
Eskişehir, 26080
Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi
Istanbul, Kartal, 34844
İstanbul Üniversitesi-Cerrahpaşa Kardiyoloji Enstitüsü
Istanbul, 34098
Kanuni Sultan Suleyman Egitim ve Arastirma Hastanesi
Istanbul, 34303
Seyrantepe Hamidiye Etfal Egitim ve Arastirma Hastanesi
Istanbul, 34371
Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi- Seyrantepe Yerleşkesi- Endokrinoloji
Istanbul, 34371
Basaksehir Cam ve Sakura Sehir Hastanesi
Istanbul, 34480
Başakşehir Çam ve Sakura Şehir Hastanesi
Istanbul, 34480
Göztepe Prof. Dr.Süleyman Yalçın Şehir Hastanesi- Dahiliye
Istanbul, 34722
Dokuz Eylül Üniversitesi Araştırma Uygulama Hastanesi-Endokrinoloji
Izmir, 35340
Kahramanmaras Sutcu Imam University
Kahramanmaraş, 46040
Erciyes Universitesi Tip Fakultesi
Kayseri, 38039
Erciyes Üniversitesi Hastanesi- Endokrinoloji
Kayseri, 38039
Erciyes Üniversitesi Hastanesi- Kardiyoloji
Kayseri, 38039
Kocaeli Universitesi Tip Fakultesi Hastanesi
Kocaeli, 41380
Kocaeli Üniversitesi Hastanesi- Kardiyoloji
Kocaeli, 41380
Kütahya Sağlık Bilimleri Üniversitesi Evliya Çelebi EAH- Kardiyoloji
Kütahya, 43040
Mersin Üniversitesi Tip Fakültesi Hastanesi- Endokrinoloji
Mersin, 33070
Mersin University Cardiology
Mersin, 33343
Mersin Üniversitesi Hastanesi- Kardiyoloji
Mersin, 33343
Marmara Üniversitesi Pendik EAH- Endokrinoloji
Pendik/istanbul, 34899
Ondokuz Mayıs Üniversitesi Hastanesi- Kardiyoloji
Samsun, 55200
Adana Şehir Eğitim ve Araştırma Hastanesi-Endokrinoloji
Yüreğir/Adana, 1370
Italy26 sites
Ente Ecclesiastico Ospedale Generale Regionale Miulli - Cardiologia e UTIC
Acquaviva delle Fonti, 70021
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
Ancona, 60126
A.O.U. Consorziale Policlinico di Bari
Bari, BA, 70124
A.O.U. Bologna_ Policlinico S.Orsola Malpighi
Bologna, 40138
A.O.U. Policlinico S.Orsola Malpighi
Bologna, 40138
A.O.U policlinico "G. Rodolico-San Marco"
Catania, 95123
Università degli studi G. D'Annunzio Chieti Pescara - CAST
Chieti, Abruzzo, 66100
AOU Careggi Firenze
Florence, Tuscany, 50134
Ospedale Santa Maria Goretti - UOD Diabetologia
Latina, LT, 04100
Azienda Ospedaliera Luigi Sacco
Milan, 20157
Azienda Ulss 3 Serenissima
Mirano, VE, 30035
Azienda Ospedaliero Universitaria di Modena
Modena, Emilia-Romagna, 41126
Azienda Ospedaliero Universitaria di Modena Ospedale Civile di Baggiovara
Modena, 41126
Azienda Ospedaliera Universitaria Federico II di Napoli
Naples, 80131
AOUP Giaccone Palermo
Palermo, Sicily, 90127
Azienda Ospedaliera-Universitaria Parma
Parma, Emilia-Romagna, 43126
ICS Maugeri
Pavia, Pv, 27100
Azienda Ospedaliero Universitaria Pisana
Pisa, 56126
Pol. Uni. Campus Biomedico UOC Endocrinologia e Diabetologia
Roma, 00128
Azienda Ospedaliero - Universitaria Sant'Andrea
Roma, 00189
Pol. Uni. Campus Biomedico - UOC Endocrinologia e Diabetologia
Rome, Lazio, 00128
Fondazione Policlinico Universitario Agostino Gemelli IRCS
Rome, RM, 00168
Policlinico San Donato S.p.A.
San Donato Milanese (MI), Lombardy, 20097
Centro di Alta Spec. Diet., Educ. Alim. e Prev. Cardio Metab
San Donato Milanese (MI), Mi, 20097
IRCCS Multimedica
Sesto San Giovanni (MI), 20099
Azienda Ospedaliera Universitaria Senese
Siena, Si, 53100
Canada23 sites
Centricity Res. Barrie Endo
Barrie, Ontario, L4N 7L3
Centricity Research Brampton Endocrinology
Brampton, Ontario, L6S 0C6
Centricity Research Calgary Endocrinology
Calgary, Alberta, T2H 2G4
Centricity Research Calgary
Calgary, Alberta, T2H 2G4
C-endo Diab Endo Clin Calgery
Calgary, Alberta, T2V 4J2
C-Health Partners
Calgary, Alberta, T2V 4J2
Cambridge Cardiac Care Centre
Cambridge, Ontario, N1R 6V6
Nova Scotia Health Authority
Halifax, Nova Scotia, B3H 1V7
Wharton Medical Clinic Clinical Trials (Hamilton)
Hamilton, Ontario, L8L 5G8
Premier Clinical Trial Research Network (PCTRN)
Hamilton, Ontario, L8M 1K7
Ctr de recherche Clinique de Laval
Laval, Quebec, H7T 2P5
Manna Research Mirabel
Mirabel, Quebec, J7J 2K8
G.A. Research Associates Ltd.
Moncton, New Brunswick, E1G 1A7
Applied Medical Informatics Research
Montreal, Quebec, H4A 3T2
Recherche Clinique Sigma Inc.
Québec, G1G 5X1
Institut universitaire de cardiologie
Québec, G1V 4G5
Diex Recherche Quebec
Québec, G1V 4T3
Clinique des Maladies Lipidiques de Quebec Inc.
Québec, G1V 4W2
Viacar Recherche Clinique Inc.
Saint-Lambert, Quebec, J4P-1S9
CHU-Sherbrooke
Sherbrooke, Quebec, J1H 5H3
Ctr de méd métab de Lanaudière
Terrebonne, Quebec, J6X 4P7
Diabetes Heart Research Centre
Toronto, Ontario, M6G 1M2
Clinical Research Solutions Inc.
Waterloo, Ontario, N2T 0C1
Japan23 sites
Akaicho Clinic
Chiba-shi, Chiba, 260-0804
Mikannohana Clinic, Diabetes, Endocrinology and Metabolism_Diabetes Internal Medicine
Ehime, 790-0034
Naka Kinen Clinic_Internal medicine
Ibaraki, 311-0113
Seino Internal Medicine Clinic
Koriyama-shi, Fukushima, Japan, 963-8851
Seino Internal Medicine Clinic_Internal medicine
Koriyama-shi, Fukushima, Fukushima, Japan, 963-8851
Jinnouchi Hospital_Internal Medicine
Kumamoto, Kumamoto, Japan, 862-0976
Tokyo Saiseikai Central Hospital
Minato-ku, Tokyo, 108-0073
Minami Akatsuka Clinic_internal medicine
Mito-shi, Ibaraki, 311-4153
Minami Akatsuka Clinic
Mito-shi, Ibaraki, 311-4153
Nanbu Tokushukai Hospital_Internal medicine
Okinawa, 901-0493
Osaka NISHI-UMEDA Clinic_Internal Medicine
Osaka, 530-0001
Nozaki Tokushukai Hospital_Internal medicine
Osaka, 574-0074
Yao Tokushukai General Hospital_Cardiovascular division
Osaka, 581-0011
Yao Tokushukai General Hospital
Osaka, 581-0011
Sakurabashi Watanabe Advanced Healthcare Hospital
Osaka-city, Osaka, 530-0005
Saga University Hospital, Department of Cardiology
Saga, 849-8501
Kagawa Prefectural Central Hospital_Cardiovascular Medicine
Takamatsu-shi, Kagawa, 760-8557
Takasaki General Medical Center_Department of Endocrinology / Metabolism Internal Medicine
Takasaki-shi, Gunma, 370-0829
Tokyo-Eki Center-building Clinic_Internal Medicine
Tokyo, 103-0027
Tokyo-Eki Center-building Clinic
Tokyo, 103-0027
Fukuwa Clinic_Internal Medicine
Tokyo, 104-0031
Japanese Red Cross Wakayama Medical Center_Diabetology and Endocrinology
Wakayama, 640-8558
National Hospital Organization Saitama Hospital_Cardiology
Wako-shi, Saitama, 351-0102
United Kingdom23 sites
Heartlands Hospital - Diabetes
Birmingham, West Midlands, B9 5SS
Blackpool Victoria Hospital
Blackpool, Lancashire, FY3 8NR
Bradford Royal Infirmary
Bradford, BD9 6RJ
The Health Centre
Bradford on Avon, BA15 1DQ
Southmead Hospital
Bristol, BS10 5NB
Countess of Chester Hospital - Diabetes
Chester, CH2 1UL
St. Richard's Hospital_Cardiology
Chichester, West Sussex, PO19 6SE
University Hospital Coventry - WISDEM Centre
Coventry, CV2 2DX
Ninewells Hospital
Dundee, DD1 9SY
Western General Hospital
Edinburgh, EH4 2XU
Royal Devon and Exeter Hospital
Exeter, EX2 5DW
Intelligent Clinical
Glasgow, G20 0XA
Hull Royal Infirmary - Diabetes
Hull, HU3 2JZ
Ipswich Hospital - Diabetes
Ipswich, IP4 5PD
St James's University Hospital - Diabetes
Leeds, LS9 7TF
Leicester General Hospital
Leicester, LE5 4PW
The Good Practice
London, SW10 0LR
NIHR Commercial Research Delivery Centre Newcastle
Newcastle upon Tyne, NE1 4LP
Derriford Hospital
Plymouth, PL6 5FP
East Surrey Hospital
Redhill, RH1 5RH
Clifton Medical Centre
Rotherham, S65 1DA
Staploe Medical Centre
Soham, CB7 5JD
Royal Cornwall Hospital (Treliske)
Truro, TR1 3LJ
South Africa20 sites
Tread Research (Pty)Ltd
Cape Town, Western Cape, 7500
Prof Rayner_Division of Nephrology
Cape Town, Western Cape, 7925
Cardiac Clinical Research Unit, University of Cape Town
Cape Town, Western Cape, 7935
Dr A Amod
Durban, KwaZulu-Natal, 4092
Netcare Umhlanga Medical Centre
Durban, KwaZulu-Natal, 4320
Dr Pillay's Rooms
Durban, KwaZulu-Natal, 4450
Lenmed Shifa Private Hospital
Durban, KwaZulu-Natal, 4901
Soweto Clinical Trial Centre
Johannesburg, Gauteng, 1818
Hemant Makan
Johannesburg, Gauteng, 1827
Wits Bara Clinical Trial Site
Johannesburg, Gauteng, 2013
Ezintsha Research Centre
Johannesburg, Gauteng, 2193
Dr Hendrik Snyman's Practice
Mossel Bay, Western Cape, 6500
Phoenix Pharma
Port Elizabeth, Eastern Cape, 6001
Prinshof Medical Campus
Pretoria, Gauteng, 0002
Dr Seeber
Pretoria, Gauteng, 0083
Dr IO Ebrahim Inc
Pretoria, Gauteng, 0157
Prof P. Joshi
Pretoria, Gauteng, 0181
Jongaie Research
Pretoria, Gauteng, 0183
Clinical Trial Systems (CTC)
Pretoria, Gauteng, 0186
Clinical Projects Research
Worcester, Western Cape, 6850
Germany19 sites
Diabeteszentrum-Do Dres. K U. Ch. Busch GbR
Dortmund, 44137
Uniklinik TU Dresden - Med. Klinik III
Dresden, 01307
Zentrum für klinische Studien Südbrandenburg GmbH
Elsterwerda, 04910
InnoDiab Forschung GmbH
Essen, 45136
MVZ CCB Frankfurt und Main-Taunus GbR
Frankfurt, 60389
Diabetes-Zentrum Wilhelmsburg
Hamburg, 21109
Diabetes-Zentrum-Wilhelmsburg GbR
Hamburg, 21109
Wendisch - Dahl Hamburg - DZHW
Hamburg, 22607
Uniklinik Heidelberg - Innere Medizin I
Heidelberg, 69120
Universitätsklinikum Leipzig - Klinik und Poliklinik für Kardiologie
Leipzig, 04103
AmBeNet GmbH
Leipzig, 04107
Diabeteszentrum Ludwigsburg
Ludwigsburg, 71634
Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
Münster, 48145
Uniklinik Münster, Klinik für Kardiologie I
Münster, 48149
Universitätsklinikum Münster - Klinik für Kardiologie I
Münster, 48149
RED-Institut für medizinische Forschung und Fortbildung GmbH
Oldenburg in Holstein, 23758
Zentrum für klinische Studien Alexander Segner
Saint Ingbert-Oberwürzbach, 66386
Al-Zoebi
Wermsdorf, 04779
Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann
Witten, 58455
Spain18 sites
H.de La Ribera_Endocrinología
Alzira, Valencia, 46600
Hosp. Comarcal de Antequera_Medicina Interna
Antequera, 29200
Hospital Vall d'Hebron
Barcelona, 08035
Hospital Vithas Sevilla
Castilleja de la Cuesta, 41950
Hospital Reina Sofia
Córdoba, 14004
Hospital Universitario de Fuenlabrada
Fuenlabrada, Madrid, 28942
Hospital Univ. de Gran Canaria Doctor Negrín
Las Palmas de Gran Canaria, 35010
Hospital Gregorio Marañón
Madrid, 28009
H. Clinico Univ. Virgen de la Victoria
Málaga, 29010
Hospital Clínico Virgen de la Victoria
Málaga, 29010
Hospital Son Espases
Palma de Mallorca, 07120
H.U. Quirónsalud Madrid
Pozuelo de Alarcón, 28223
Hospital Quirón
Pozuelo de Alarcón, 28223
H Virgen del Camino_Sanlúcar_Medicina Interna
Sanlúcar de Barrameda, 11540
Clínica Nuevas Tecnologías en Diabetes y Endocrinología
Seville, 41003
Hospital Universitario Virgen del Rocío
Seville, 41013
Hospital General Universitario de Toledo
Toledo, 45007
Hospital General de Valencia
Valencia, 46014
Argentina17 sites
CIPREC Pueyrredon
Buenos Aires, C1119ACN
Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
Buenos Aires, C1425AGC
Mautalen Salud e investigación
CABA, Buenos Aires, C1128 AAF
CEMEDIC
CABA, Buenos Aires, C1440CFD
CEDIC Centro de Investigación Clínica
CABA, C1060ABA
CIPREC Arenales
CABA, C1061AAS.
CENUDIAB Centro Médico de Nutrición v Diabetes
CABA, C1440AAD
Medical Center of Diabetes and Nutrition
CABA, C1440AAD
Centro de Investigaciones Metabólicas
Capital Federal, Buenos Aires, C1056ABI
Instituto Médico DAMIC
Córdoba, X5003DCE
Centro Médico Privado San Vicente Diabetes
Córdoba, X5006IKK
Hospital Italiano de la Plata
La Plata, Buenos Aires, B 1900AXI
Instituto de Investigaciones Clinicas Mar Del Plata
Mar del Plata, Buenos Aires, B7600FZN
Consultorio Integral de Atención al Diabético
Morón, B1708IFF
Instituto Medico Catamarca
Rosario, Santa Fe Province, S2000
Instituto de Investigaciones Clinicas San Nicolás
San Nicolás, B2900
Sanatorio Norte
Santiago del Estero, G4200
Australia16 sites
Nightingale Research Adelaide
Adelaide, South Australia, 5000
Royal Adelaide Hospital - Cardiology Department
Adelaide, South Australia, 5000
Advara HeartCare Auchenflower
Auchenflower, Queensland, 4066
Gosford Renal Research
Gosford, New South Wales, 2250
Royal Hobart Hospital
Hobart, Tasmania, 7000
Advara HeartCare Joondalup
Joondalup, Western Australia, 6027
Paratus Clinical
Kanwal, New South Wales, 2259
Southern Neurology
Kogarah, New South Wales, 2217
Advara HeartCare Leabrook
Leabrook, South Australia, 5068
Liverpool Hospital
Liverpool, New South Wales, 2170
Macquarie University - Clinical Trials Unit
Macquarie Park, New South Wales, 2109
Logan Hospital
Meadowbrook, Queensland, 4131
Baker Heart and Diabetes Institute
Melbourne, Victoria, 3004
One Clinical Research
Nedlands, Western Australia, 6009
Clinitrials
Perth, Western Australia, 6000
Clinitrials
West Perth, Western Australia, 6005
Malaysia16 sites
Hospital Ampang
Ampang, Selangor, 68000
Hospital Pulau Pinang
George Town, Pulau Pinang, 10450
Hospital Serdang
Kajang, Selangor, 43000
Hospital Tengku Ampuan Afzan
Kuantan, Pahang, 25100
Sarawak General Hospital
Kuching, Sarawak, 93586
University Malaya Medical Centre
Lembah Pantai, Kuala Lumpur, 59100
Hospital Melaka
Malacca, 75400
Hospital Miri
Miri, Sarawak, 98000
Hospital Putrajaya
Putrajaya, 62250
Hospital Miri
Sarawak, 98000
Hospital Ampang
Selangor Darul Ehsan, 68000
Hospital Seri Manjung
Seri Manjung, Perak, 32040
Hospital Shah Alam
Shah Alam, 40000
Hospital Sibu
Sibu, Sarawak, 96000
Hospital Sultan Haji Ahmad Shah
Temerluh, Pahang, 28000
Hospital Putrajaya
Wilayah Persekutuan Putrajaya, 62250
Brazil15 sites
Instituto de Pesquisa Clínica de Campinas
Campinas, São Paulo, 13060-080
PUCCAMP - Hospital e Maternidade Celso Pierro
Campinas, São Paulo, 13060-803
i9 Pesquisas Clínicas
Campinas, São Paulo, 13092-133
Núcleo de Pesquisa Clínica S/S
Curitiba, Paraná, 80730-150
Centro de Pesquisa em Diabetes Doenças Endócrino-Metabólicas
Fortaleza, Ceará, 60430-350
CPHosp Manaus Medicina, Ensino e Pesquisa LTDA
Manaus, Amazonas, 69057-088
Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.
Porto Alegre, Rio Grande do Sul, 90430-001
Hospital São Lucas Copacabana
Rio de Janeiro, 22061-080
CIP Centro Integrado de Pesquisas do Hospital de Base
São José do Rio Preto, São Paulo, 15090-000
Instituto São José dos Campos em Pesquisas Médicas
São José dos Campos, São Paulo, 12243-280
Instituto de Pesquisa Clinica (IPEC)
São Paulo, São Paulo, 01223-001
CPQuali Pesquisa Clínica Ltda
São Paulo, São Paulo, 01228-000
CPCLIN - Centro de Pesquisas Clínicas
São Paulo, São Paulo, 01228-200
CEPIC - Centro Paulista de Investigacao Clinica
São Paulo, 04266-010
Centro de Diag. e Pesquisa da Osteoporose do Espírito Santo
Vitória, Espírito Santo, 29055-450
Thailand15 sites
Siriraj Hospital
Bangkok, Bangkok Noi, 10700
Vajira Hospital - Cardio
Bangkok, 10300
King Chulalongkorn Memorial Hospital
Bangkok, 10330
Phramongkutklao Hospital_Neurology
Bangkok, 10400
Phramongkutklao Hospital
Bangkok, 10400
Rajavithi Hospital_Diabetes and Endocrinology
Bangkok, 10400
Ramathibodi Hospital
Bangkok, 10400
Siriraj Hospital
Bangkok, 10700
Maharaj Nakorn Chiang Mai
Chiang Mai, 50200
RIHES-CMU_Research Institute for Health Sciences
Chiang Mai, 50200
Chiang Rai Prachanukroh Hospital
Chiang Rai, 57000
Srinagarind Hospital
Khon Kaen, 40002
Maharat Nakhon Ratchasima Hospital
Nakhon Ratchasima, 30000
Thammasat Hospital_Cardiology
Pathum Thani, 12120
Songklanagarind Hospital
Songkhla, Had-Yai, 90110
France14 sites
Centre Hospitalier d'Annonay
Annonay, 07100
Centre Hospitalier Ardeche Nord
Annonay, 07103
Ap-Hp-Hopital Avicenne
Bobigny, 93000
Centre Hospitalier Universitaire Grenoble Alpes-Site Nord Michallon-2
Grenoble, 38043
CH Louis Pasteur
Le Coudray, 28630
Les Hopitaux de Chartres-Hopital Louis Pasteur
Le Coudray, 28630
Groupe Hospitalier Du Havre
Le Havre, 76600
Centre Hospitalier Universitaire de Lille-Hopital Claude Huriez
Lille, 59000
Centre Hospitalier Universitaire de Montpellier-Hopital Lapeyronie
Montpellier, 34090
Aphp-Hopital La Pitie Salpetriere-2
Paris, 75013
Hopital Novo
Pontoise, 95300
Centre Hospitalier Bretagne Atlantique
Vannes, 56000
Centre de Recherche Clinique Portes Du Sud
Vénissieux, 69200
RESEAU DE SANTE MUTUALISTE-Médipôle Hôpital Mutualiste
Villeurbanne, 69100
Mexico13 sites
Promotora Medica Aguascalientes SA de CV
Aguascalientes, 20230
Centro de Estudios de Investigación Metabólicos y Cardio
Ciudad Madero, Tamaulipas, 89440
Instituto de Diabetes Obesidad y Nutricion S.C.
Cuernavaca, Morelos, 62250
Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada, S.C.
Culiacán, Sinaloa, 80230
Centro para el Desarrollo de la Medicina y la Asistencia
Culiacán, Sinaloa, 80230
Centro de Investigacion Clinica Endocrinologica de Jalisco
Guadalajara, Jalisco, 44670
Virgen Cardiovascular Research SC
Guadalajara, Jalisco, 44670
Internal Medicine Clin Trials
Monterrey, Nuevo León, 64020
Cardiolink Clin Trials S.C.
Monterrey, Nuevo León, 64060
Unidad Biomedica Avanzada Monterrey
Monterrey, Nuevo León, 64460
Clínica García Flores
Monterrey, Nuevo León, 64610
Centro de atención e investigación cardiovascular del Potosí
San Luis Potosí City, San Luis Potosí, 78200
Consultorio 1020 Hospital Angeles Xalapa
Xalapa, Veracruz, 91193
Denmark10 sites
Aarhus Universitetshospital, Hjertesygdomme
Aarhus N, Central Jutland, 8200
Aarhus Universitetshospital, Steno Diabetes Center Aarhus
Aarhus N, 8200
Herlev Hospital - Afdeling for Hjertesygdomme, Forskning 1
Herlev, Capital Region, 2730
Regionshospitalet Gødstrup, Hjertesygdomme
Herning, 7400
Hillerød Endokrinologisk amb. H0652
Hillerød, 3400
Holbæk Sygehus - Forskningsenheden, Medicinsk Afdeling, afs. 44-4
Holbæk, Region Sjælland, 4300
Kolding Sygehus Karkirurgi
Kolding, 6000
Slagelse Sygehus Ambulatorium for hjertesygdomme
Slagelse, 4200
Svendborg Sygehus - Kardiologisk
Svendborg, Region South, 5700
Viborg Sygehus
Viborg, 8800
Netherlands9 sites
Gelre Zkh Apeldoorn
Apeldoorn, 7334 DZ
Maxima MC Eindhoven
Eindhoven, 5631 BM
Groene Hart Zkh Gouda
Gouda, 2803HH
UMC Groningen
Groningen, 9713 GZ
Frisius MC Leeuwarden
Leeuwarden, 8934 AD
RadboudUMC
Nijmegen, 6525 GA
Franciscus Gasthuis en Vlietland
Rotterdam, 3045 PM
D & A Research B.V.
Sneek, 8601 ZR
Zkh Rivierenland Tiel - Cardiologie
Tiel, 4002 WP
Serbia9 sites
CHC Zvezdara, Clinical department for endocrinology
Belgrade, 11000
Endocrinology, Diabetes and Metabolism Diseases Clinic
Belgrade, 11000
Military Medical Academy
Belgrade, 11000
Clinical Hospital Center Bezanijska Kosa
Belgrade, 11080
Clinical Centre Kragujevac, Internal Diseases Clinic, Endocrinology department
Kragujevac, 34000
University Clinical Centre Nis
Niš, RS, 18 000
Clinical Centre Nis, Endocrinology, Diabetes and Metabolism
Niš, RS, 18000
Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.
Novi Sad, Vojvodina, 21000
Policlinic for diabetes
Zaječar, 19000
Colombia8 sites
Clinica de la Costa
Barranquilla, Atlántico, 80020
Fundacion del Caribe para la Investigacion Biomedica-BIOS
Barranquilla, 080020
CentrodeInvestigaciónenReumatologíayEspecialidadesMédicas
Bogotá, 110221
Unidad de Estudios Clínicos de la Fundación Cardiovascular de Colombia
Bucaramanga-piedecuesta, Valle Del Menzuli - Santander, Santander Department, 681012
FOSCAL
Floridablanca, Santander Department, 681004
Servicios de Salud Ips Suramericana S.A.S.
Medellín, Antioquia, 05001
Somer Sociedad Medica Rionegro S.A. Somer S.A.
Rionegro, 054040
Fundación Hospital Universidad del Norte
Soledad, Barranquilla, 83001
Ireland7 sites
Clinical Research Centre, St. Vincent's University Hospital,
Dublin, Leinster, D04 T6F4
Mater Miscericordiae Hospital
Dublin, Leinster, D07 XAO9
St James's CRF
Dublin, Leinster, D08 A978
Connolly Hospital_Blanchardstown_Diabetes Day Centre
Dublin, Leinster, D15 X40D
Mater Miscericordiae Hospital
Dublin, Leinster, DUBLIN 7
CRF - Galway
Galway, Connaght, H91 YR71
CRF HRB - Galway
Galway, Connaght, H91 YR71
About this study
Official title: The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.
- Conditions
- Cardiovascular Disease
- Being tested
- Cagrilintide, Semaglutide, Placebo
- Medical subject headings
- Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CagrilintideDrug
Participants will receive cagrilintide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
SemaglutideDrug
Participants will receive semaglutide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
PlaceboDrug
Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.
| Study group | Role | What they receive |
|---|---|---|
| CagriSema | Experimental | Participants will receive cagrilintide and semaglutide subcutaneously (s.c.) once-weekly after a dose escalation period of 16 weeks during the maintenance period of 219 weeks. Receives: Drug: Cagrilintide; Drug: Semaglutide |
| Placebo | Placebo comparator | Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide s.c. once weekly for 235 weeks. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke
Measured in days.
Measured: From baseline (week 0) to end of study (up to 242 weeks or more)
Secondary outcomes (18)
Time to first occurrence of a composite endpoint: Onset of persistent ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy, Kidney death and CV death
CKD-EPI is Chronic Kidney Disease Epidemiology Collaboration. Measured in days.
Measured: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of composite endpoint consisting of: Onset of persistent macro albuminuria, ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy and kidney death
CKD-EPI is Chronic Kidney Disease Epidemiology Collaboration. Measured in days.
Measured: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of an expanded 5-point MACE composite endpoint consisting of: CV death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation and unstable angina requiring hospitalisation
Measured in days.
Measured: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of a composite endpoint consisting of: all-cause death, non-fatal myocardial infarction and non-fatal stroke
Measured in days.
Measured: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of myocardial infarction (fatal and non-fatal)
Measured in days.
Measured: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of stroke (fatal and non-fatal)
Measured in days.
Measured: From baseline (week 0) to end of study (up to 242 weeks or more)
Change in eGFRcr (CKD-EPI)
Measured in milliliter per min per 1.73 square meter (mL/min/1.73m^2).
Measured: From baseline (week 0) to 120 weeks
Ratio to baseline in Urine albumin-to-creatinine ratio (UACR)
Measured in ratio.
Measured: From baseline (week 0) to 120 weeks
Relative change in body weight
Measured in percentage (%).
Measured: From baseline (week 0) to 120 weeks
Change in waist circumference
Measured in centimeters (cm).
Measured: From baseline (week 0) to 120 weeks
Change in waist-to-height ratio
Measured in ratio.
Measured: From baseline (week 0) to 120 weeks
Change in systolic blood pressure (SBP)
Measured in millimeters of mercury (mmHg).
Measured: From baseline (week 0) to 120 weeks
Change in diastolic blood pressure (DBP)
Measured in mmHg.
Measured: From baseline (week 0) to 120 weeks
Ratio to baseline in lipids: Total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids
Measured in ratio.
Measured: From baseline (week 0) to 120 weeks
Change in glycated haemoglobin (HbA1c)
Measured in percentage-points.
Measured: From baseline (week 0) to 120 weeks
Number of treatment emergent serious adverse events (TESAEs)
Measured in count of events.
Measured: From baseline (week 0) to end of study (up to 242 weeks or more)
Number of event adjudication committee (EAC)-confirmed malignant neoplasms
Measured as count of events.
Measured: From baseline (week 0) to end of study (up to 242 weeks or more)
Number of severe hypoglycaemic episodes (level 3) (only for participants with type 2 diabetes mellitus [T2D] at screening)
Measured as count of events.
Measured: From baseline (week 0) to end of study (up to 242 weeks or more)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jan 2023
- Study start1 Mar 2023
- Primary completion1 Sep 2027 (estimated)
- Study completion14 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseaseStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 7,101 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Transparency dept. 2834, Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05669755
- Sponsor's protocol ID
- NN9838-4942
- Other IDs
- U1111-1270-0943, 2021-005855-35, jRCT2031220672
- Acronym
- REDEFINE 3
- Status last verified
- Aug 2026
- First submitted
- 20 Dec 2022
- Last updated
- 31 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Publications
Cavender MA, Jastreboff AM, Cheng AYY, Davies MJ, Donaldson L, Gerlach LO, Gylvin SH, Jacobsen JB, Marx N, Osorto Contreras CK, Le Roux CW, Lincoff AM. Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3). Am Heart J. 2026 Oct 6:107626. doi: 10.1016/j.ahj.2026.107626. Online ahead of print.
PubMed 42838477
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease
- ClinicalTrials.gov ID
- NCT05669755
- Acronym / sponsor ID
- REDEFINE 3 / NN9838-4942
- Conditions
- Cardiovascular Disease
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 7,101 participants (actual)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 1 Mar 2023 (actual)
- Primary completion
- 1 Sep 2027 (estimated)
- Study completion
- 14 Oct 2027 (estimated)
- First posted
- 3 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CagriSema | Experimental | Drug: Cagrilintide, Drug: SemaglutideParticipants will receive cagrilintide and semaglutide subcutaneously (s.c.) once-weekly after a dose escalation period of 16 weeks during the maintenance period of 219 weeks. |
| Placebo | Placebo comparator | Drug: PlaceboParticipants will receive placebo matched to cagrilintide and placebo matched to semaglutide s.c. once weekly for 235 weeks. |
Who may qualify
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (18 listed)
- Male or female
- Age above or equal to 55 years at the time of signing informed consent
- Body mass index (BMI) greater than or equal to (>=) 25.0 kilograms per meter square (kg/m^2)
- Established CVD as evidenced by at least one of the following:
- Diagnosed with type 2 diabetes mellitus (T2D) >= 180 days before screening
Key exclusion criteria (6 listed)
- Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 60 days before screening
- Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
- Heart failure classified as being in New York Heart Association (NYHA) Class IV at screening
- Treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist (RA) or a medication with GLP-1 activity within 90 days before screening
- End stage renal disease defined as estimated glomerular filtration rate (eGFR) < 15 millileters per minutes per 1.73^2 (mL/min/1.73 m^2), as measured by the central laboratory at screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CagrilintideParticipants will receive cagrilintide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks. | Drug | CagriSema |
| SemaglutideParticipants will receive semaglutide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks. | Drug | CagriSema |
| PlaceboParticipants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously. | Drug | Placebo |
Primary outcome
Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Measured in days.
18 secondary outcomes
Time to first occurrence of a composite endpoint: Onset of persistent ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy, Kidney death and CV death
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of composite endpoint consisting of: Onset of persistent macro albuminuria, ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy and kidney death
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of an expanded 5-point MACE composite endpoint consisting of: CV death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation and unstable angina requiring hospitalisation
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of a composite endpoint consisting of: all-cause death, non-fatal myocardial infarction and non-fatal stroke
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of myocardial infarction (fatal and non-fatal)
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of stroke (fatal and non-fatal)
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Change in eGFRcr (CKD-EPI)
Time frame: From baseline (week 0) to 120 weeks
Ratio to baseline in Urine albumin-to-creatinine ratio (UACR)
Time frame: From baseline (week 0) to 120 weeks
Relative change in body weight
Time frame: From baseline (week 0) to 120 weeks
Change in waist circumference
Time frame: From baseline (week 0) to 120 weeks
Change in waist-to-height ratio
Time frame: From baseline (week 0) to 120 weeks
Change in systolic blood pressure (SBP)
Time frame: From baseline (week 0) to 120 weeks
Change in diastolic blood pressure (DBP)
Time frame: From baseline (week 0) to 120 weeks
Ratio to baseline in lipids: Total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids
Time frame: From baseline (week 0) to 120 weeks
Change in glycated haemoglobin (HbA1c)
Time frame: From baseline (week 0) to 120 weeks
Number of treatment emergent serious adverse events (TESAEs)
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Number of event adjudication committee (EAC)-confirmed malignant neoplasms
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Number of severe hypoglycaemic episodes (level 3) (only for participants with type 2 diabetes mellitus [T2D] at screening)
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2026.
- Derived from this study: PubMed 42838477Cavender MA, Jastreboff AM, Cheng AYY, Davies MJ, Donaldson L, Gerlach LO, Gylvin SH, Jacobsen JB, Marx N, Osorto Contreras CK, Le Roux CW, Lincoff AM. Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3). Am Heart J. 2026 Oct 6:107626. doi: 10.1016/j.ahj.2026.107626. Online ahead of print.
- Individual participant dataSharing planned: Yes. According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Related trials for Cardiovascular Disease
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Transparency dept. 2834 study director
Novo Nordisk A/S
633 sites in 25 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Cagrilintide and Semaglutide in people with Cardiovascular Disease, run by Novo Nordisk A/S at 633 sites in 25 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 31 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 633 sites in United States, India, Poland, Bulgaria, Turkey (Türkiye) and 20 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke (time frame: From baseline (week 0) to end of study (up to 242 weeks or more)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05669755, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2026.